Infobip Achieves GSMA Open Gateway Certifications for Network APIs
16.9.2025 10:00:00 CEST | Business Wire | Press Release
Global communications platform Infobiphas received two new Network API certifications from the GSMA, as part of the CAMARA project. The SIM Swap and Number Verification certifications demonstrate Infobip's commitment to advancing global standards for Network APIs through the GSMA Open Gateway initiative.
The certifications mark a significant milestone for Infobip and its telco partners worldwide. The certifications validate Infobip's expertise and support mobile network operators (MNOs) in achieving their own certifications as part of GSMA's global standardization efforts.
Viktorija Radman, Telecom Growth & Strategy Director at Infobip, said:"Achieving GSMA certifications for SIM Swap and Number Verification demonstrates our commitment to building secure, scalable solutions for operators worldwide. As a CPaaS enabler, Infobip is dedicated to helping telcos embrace new global standards and bring the benefits of Network APIs to real-world use cases. With its experience, partnerships, and developer-first approach, Infobip is helping telcos worldwide unlock new business opportunities and accelerate digital transformation."
Real-world impact
Infobip has several successful partnerships launching CAMARA-compliant Network APIs under the GSMA Open Gateway initiative. For instance, Infobip, together with four major French mobile operators, demonstrated what network APIs combined with reach channels like RCS can do to combat fraud and improve digital trust and security in the banking industry. The company also helped all Brazilian operators implement and market Number Verification, SIM SWAP detection, KYC and device location APIs to help businesses and developers speed up verification, reduce the likelihood of errors, increase conversions and fight fraud.
At Shift Zadar, Infobip will co-host an Ideathon at Shift Zadar in Croatia, alongside GSMA, CAMARA, and Orange.“Developers will explore and build use cases with certified Network APIs, including SIM Swap, Number Verification, Device Location and Know Your Customer (KYC) Match. This initiative reinforces the relevance of showcasing the scalable use of Network APIs amongst developers, and GSMA is honored to join and be one of the main drivers of this key moment at the conference,”said Henry Calvert, Head of Networks at GSMA.
Cédric Gonin, Director of Telco API Business Strategy & Channel Management at Orange Livenet, said: “Infobip is helping to drive innovation in the telco ecosystem through its adoption and implementation of Network APIs for MNOs. Orange is at the forefront of these developments. At Infobip’s Shift Zadar conference, we will demonstrate how such tools can better serve our customers and protect them from fraud while helping develop the telco ecosystem globally.”
New awards
Infobip has won Frost & Sullivan's 2025 Global Customer Value Leadership Award for Network APIs. Frost & Sullivan recognized Infobip for its ability to drive the Network API ecosystem into its next growth phase, capturing market share and sustaining its leadership in the coming years.
Infobip distinguishes itself as a frontrunner in network application programming interface solutions, building on its deep expertise in communication platforms as a service offering and extensive CSP relationships.
About Infobip
Infobip is a global cloud communications platform that enables businesses to build connected experiences across all stages of the customer journey.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250916538370/en/
Contacts
For more information:
Marcelo Nahime
marcelo.nahime@infobip.com
Bojana Mandić
Bojana.Mandic1@infobip.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom